HSIC

Henry Schein, Inc. (HSIC) stock has fluctuated in the past six months due to earnings reports and market sentiment, with prices ranging from $61.95 to $89.29 over the past year. On May 5, 2026, the company reported strong first-quarter results, exceeding EPS and revenue estimates, but the stock dipped 5.5% the following week. Management reaffirmed its full-year 2026 guidance, projecting sales growth of 3% to 5% and non-GAAP diluted EPS between $5.23 and $5.37. A light flu season impacted the medical segment's performance in Q1 2026. The company repurchased 1.6 million shares for $125 million during the quarter. Analyst ratings are mixed, with some firms issuing "Buy" ratings and others maintaining a "Neutral" stance.